logo
Plus   Neg
Share
Email

Target Boosts FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter on Wednesday, retailer Target Corp. (TGT) initiated adjusted earnings and comparable sales guidance for the third quarter as well as raised adjusted earnings guidance for the full-year 2019.

For the third quarter, Target expects comparable sales growth of 3.4 percent, with both earnings from continuing operations and adjusted earnings to be in a range of $1.04 to $1.24 per share.

Looking ahead to fiscal 2019, the retailer raised its guidance for both earnings from continuing operations and adjusted earnings to a range of $5.90 to $6.20 per share from the prior outlook range of $5.75 to $6.05 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.62 per share for the third quarter and $5.93 per share for the year. Analysts' estimates typically exclude special items.

Additionally, the company reported second-quarter comparable sales growth of 3.4 percent on traffic growth of 2.4 percent. Comparable store sales grew 1.5 percent, and comparable digital sales grew 1.8 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>